Noble Financial Capital Markets acts as Co-Manager of Galena Biopharma, Inc. (GALE) $35million publically underwritten transaction
About Galena Biopharma, Inc. (GALE)
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. The company’s lead product candidate includes NeuVax (nelipepimut-S or E75), which is in Phase 3 clinical trials for preventing the recurrence of breast cancer. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trials for the prevention of recurrence in gynecological cancers, such as ovarian and endometrial adenocarconimas.
Healthcare Investment Banking Group
Shawn Titcomb
Managing Director
Direct: 561.998.5480
Cell: 561.706.3250
stitcomb@noblefcm.com
Francisco Penafiel
Associate
Direct: 561.994.5740
fpenafiel@noblefcm.com
About Noble Financial Capital Markets
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on healthcare, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial will host its large format, 10th annual, equity conference at Club Med (full resort buyout) on January 19-22, 2014 located 40 minutes north of Palm Beach Airport in South Florida. The Conference will feature 150 presenting companies from across North America and total attendance of close to 600. Members: FINRA, SIPC, MSRB